Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET plus LAP) versus anastrozole plus trastuzumab (ANA plus TZ) as first-line treatment for postmenopausal women with HER2+and HR+ metastatic breast cancer (MBC) from the UK National Health Service (NHS) perspective

被引：1
|
作者：
Hastings, V.
Delea, T. E.
Amonkar, M.
Lykopoulos, K.
Diaz, J.
Johnston, S. R.
机构：
[1] Policy Anal Inc, Brookline, MA USA
[2] GlaxoSmithKline, Collegeville, PA USA
[3] GlaxoSmithKline Global Hlth Outcomes, London, England
[4] GlaxoSmithKline Hllth Outcomes Oncol, London, England
[5] Royal Marsden NHS Fdn Trust, Inst Canc Res, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1035
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB plus ANASTROZOLE COMPARED TO LAPATINIB plus LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR plus ) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)
    McNamara, S.
    Moore, L.
    Ray, J.
    VALUE IN HEALTH, 2010, 13 (07) : A269 - A269
  • [2] Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective
    Mistry, Rohit
    May, Jessica R.
    Suri, Gaurav
    Young, Kate
    Brixner, Diana
    Oderda, Gary
    Biskupiak, Joseph
    Tang, Derek
    Bhattacharyya, Subrata
    Mishra, Dinesh
    Bhattacharyya, Devarshi
    Dalal, Anand A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (06): : 514 - +
  • [3] Cost-effectiveness of lapatinib plus capecitabine (LAP plus C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ plus C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the UK National Health Service (NHS) perspective
    Sofrygin, O.
    Delea, T. E.
    Tappenden, P.
    Karnon, J.
    Browning, D.
    Amonkar, M.
    Lykopoulos, K.
    Cameron, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2-locally advanced or metastatic breast cancer: a Brazilian private payer perspective
    Buehler, Anna Maria
    Castilho, Gabriela
    Dionne, Pierre-Alexandre
    Stefani, Stephen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [5] Cost-effectiveness (CE) of lapatinib plus capecitabine (L plus C) in women with ErbB2+(HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective
    Delea, T. E.
    Tappenden, P.
    Sofrygin, O.
    Karnon, J.
    Amonkar, M.
    Browning, D.
    Rudge, H.
    Walker, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 225 - 225
  • [6] COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED/METASTATIC BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE
    Hettle, R.
    Suri, G.
    Misty, R.
    Chandiwana, D.
    Lee, A.
    VALUE IN HEALTH, 2017, 20 (09) : A433 - A433
  • [7] Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2-Advanced Breast Cancer
    Fasching, Peter A.
    Delea, Thomas E.
    Lu, Yen-Shen
    De Boer, Richard
    Hurvitz, Sara A.
    Moynahan, Aaron
    Chandiwana, David
    Lanoue, Brad
    Hu, Huilin
    Thuerigen, Astrid
    O'Shaughnessy, Joyce
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8179 - 8189
  • [8] COST-EFFECTIVENESS OF PALBOCICLIB PLUS LETROZOLE IN THE TREATMENT OF HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN ECUADOR
    Cabezas, M.
    Freire, V
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [9] Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2-advanced breast cancer
    Jhaveri, Komal
    O'Shaughnessy, Joyce
    Fasching, Peter A.
    Tolaney, Sara M.
    Yardley, Denise A.
    Sharma, Vikash Kumar
    Biswas, Chandroday
    Thuerigen, Astrid
    Pathak, Purnima
    Rugo, Hope S.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [10] Comparison of the cost-effectiveness of upfront letrozole or anastrozole versus tamoxifen for early breast cancer in hormone receptor positive (HR plus ) postmenopausal women the Cypriot perspective
    Andreopoulos, D.
    Karnon, J.
    Kaura, S.
    EJC SUPPLEMENTS, 2008, 6 (07): : 126 - 127
12345